Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORTHO-NOVUM 7/7/7-28 vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of estrogen (ethinyl estradiol) and progestin (norethindrone) inhibits gonadotropin secretion, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet orally once daily for 28 consecutive days (21 active tablets followed by 7 placebo tablets). Each active tablet contains 0.035 mg ethinyl estradiol and varying progestin doses: 7 tablets of 0.5 mg norethindrone, 7 tablets of 0.75 mg norethindrone, and 7 tablets of 1 mg norethindrone.
400 mg orally once daily with food.
EE: terminal half-life 13-27 hours (mean ~17 hours); NET: 7-13 hours (mean ~10 hours). Clinical context: steady state reached after 4-7 days; missed pills may reduce contraceptive efficacy.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Ethinyl estradiol and norethindrone undergo hepatic metabolism via CYP3A4 and other CYP450 enzymes. Conjugation and sulfation also occur.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Ethinyl estradiol (EE) is excreted in urine (40%) and feces (60%) as glucuronide and sulfate conjugates. Norethindrone (NET) is excreted primarily in urine (60-80%) as glucuronide conjugates, with 10% in feces. Biliary excretion contributes minimally.
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
EE: 98% bound to albumin; induces SHBG synthesis, increasing binding capacity. NET: 61% bound to albumin, 36% bound to SHBG.
98% bound to albumin
EE: 2.5-5.0 L/kg (mean 4 L/kg); large Vd due to extensive tissue distribution. NET: 1.5-4.0 L/kg (mean 2.5 L/kg); distributes into breast milk.
0.2-0.3 L/kg; indicates limited extravascular distribution
EE: 38-48% due to first-pass metabolism (sulfation in gut wall and 2-hydroxylation in liver). NET: 50-77% (mean 64%) with high first-pass metabolism.
Oral: 85-90%; IM: 95-100%
No specific dosage adjustments recommended for renal impairment. Use with caution in severe renal impairment due to potential for fluid retention and hypertension.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in acute hepatitis, severe cirrhosis, or liver tumors. For mild hepatic impairment (Child-Pugh A), use with caution; no specific dose adjustment established. Not recommended in moderate to severe impairment (Child-Pugh B or C) due to reduced metabolism of steroid hormones.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not indicated for premenarchal girls. For postmenarchal adolescents, dosage is the same as adults (one tablet daily) but initiation should be based on clinical judgment and individual risk factors.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for postmenopausal women. No specific dosing recommendations; use not appropriate in this age group due to lack of contraceptive need and potential increased risk of vascular events.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (>15 cigarettes/day). Women over 35 who smoke should not use this product.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Increased risk of thromboembolic disorders; use caution in patients with cardiovascular risk factors. Monitor blood pressure. Discontinue if jaundice, visual disturbances, or migraine occurs. May affect glucose tolerance. Use with caution in patients with history of depression.
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Thrombophlebitis or thromboembolic disorders; history of deep vein thrombosis or pulmonary embolism; cerebrovascular or coronary artery disease; known or suspected breast cancer; endometrial cancer or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component; cigarette smoking in women over age 35.
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No specific food restrictions; grapefruit juice may increase ethinyl estradiol levels and should be avoided or minimized. High-fat meals may slightly increase absorption but not clinically significant.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
Combined hormonal contraceptives (CHCs) including ORTHO-NOVUM 7/7/7-28 are contraindicated during pregnancy. First trimester exposure: no consistent evidence of major malformations (e.g., VACTERL) from epidemiologic studies, but a small increased risk of cardiovascular defects and limb reduction defects cannot be excluded. Second and third trimester exposure: risk of maternal and fetal adverse outcomes, including fetal growth restriction, preterm delivery, and potential masculinization of female fetuses from progestins. Use is contraindicated once pregnancy is suspected or confirmed.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
CHCs like ORTHO-NOVUM 7/7/7-28 may reduce milk production and quality, especially in early postpartum. Small amounts of ethinyl estradiol and norethindrone are excreted into breast milk; estimated infant dose is <1% of maternal weight-adjusted dose. Milk-to-plasma (M/P) ratio for norethindrone is approximately 0.1–0.5; ethinyl estradiol M/P ratio is not well defined. Use during lactation is generally not recommended; progestin-only contraceptives are preferred. If used, initiate after established breastfeeding (≥6 months).
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
ORTHO-NOVUM 7/7/7-28 is contraindicated during pregnancy. No dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are not relevant due to contraindication.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
Fixed-dose combination of norethindrone and ethinyl estradiol; pill sequence has 7 white (0.5mg norethindrone/35mcg EE), 7 light peach (0.75mg/35mcg), 7 peach (1mg/35mcg), 7 green (placebo). Missed pills increase breakthrough bleeding risk; if one pill missed, take as soon as remembered; if two or more, use backup contraception for 7 days. Consider progestin-only alternatives in patients with migraine with aura, uncontrolled hypertension, or smoking >35. Potential for reduced efficacy with enzyme-inducing antiepileptics (e.g., carbamazepine) and rifampin. Increased VTE risk, especially in first year of use. Estrogen-containing contraceptives can increase hepatic clearance of some drugs. Not suitable for breastfeeding within first 6 weeks postpartum due to estrogen effect on milk supply.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one pill daily at the same time; start on first day of menstrual period or first Sunday after period begins (check package instructions).,The pill pack has 3 different colored active pills (white, light peach, peach) with increasing progestin dose, followed by 7 green placebo pills; continue taking daily even during placebo week.,If you miss one active pill, take it as soon as remembered and take next pill at usual time (may take 2 pills in one day).,If two or more active pills are missed, take the last missed pill now, discard others, continue with remaining pills; use backup contraception (e.g., condoms) for next 7 days.,Common side effects: nausea, breast tenderness, spotting (especially in first few months); report leg swelling, chest pain, severe headache, or vision changes.,Avoid grapefruit juice as it may increase estrogen levels; no known food restrictions otherwise.,Smoking increases risk of serious cardiovascular events; advise smoking cessation.,Do not use while pregnant; if pregnancy suspected, discontinue and consult healthcare provider.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORTHO-NOVUM 7/7/7-28 vs ADQUEY, answered by our medical review team.
ORTHO-NOVUM 7/7/7-28 is a Oral Contraceptive that works by Combination of estrogen (ethinyl estradiol) and progestin (norethindrone) inhibits gonadotropin secretion, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORTHO-NOVUM 7/7/7-28 and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORTHO-NOVUM 7/7/7-28 is: One tablet orally once daily for 28 consecutive days (21 active tablets followed by 7 placebo tablets). Each active tablet contains 0.035 mg ethinyl estradiol and varying progestin doses: 7 tablets of 0.5 mg norethindrone, 7 tablets of 0.75 mg norethindrone, and 7 tablets of 1 mg norethindrone.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORTHO-NOVUM 7/7/7-28 and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORTHO-NOVUM 7/7/7-28 is classified as Category C. Combined hormonal contraceptives (CHCs) including ORTHO-NOVUM 7/7/7-28 are contraindicated during pregnancy. First trimester exposure: no consistent evidence of major malformations. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.